DOWNERS GROVE, Ill., May 2, 2017 /CNW/ -- Univar Canada Ltd., a subsidiary of Univar Inc. (NYSE: UNVR) ("Univar"), a global chemical and ingredient distributor and provider of value-added services, has entered into an agreement with Siegfried AG for distribution of Siegfried's portfolio of active pharmaceutical ingredients (API) for the Canadian market.
"Navigating regulatory compliance for the import of active pharmaceutical ingredients has become an important value driver for the pharmaceutical industry in Canada," said Willy St. Cyr, Vice President of Product and Industry Development and Sales Operations at Univar. "Working closely with Siegfried, which has a long-standing pharma and chemical heritage, will allow us to provide customers in the industry with a reliable resource for APIs that meets today's regulatory needs and delivers increased synergy, expertise and value while providing attractive new growth for Siegfried."
Craig Douglas, Global Head API Portfolio Sales at Siegfried adds, "We are delighted to team up with Univar for the distribution of our API portfolio in Canada. Our API portfolio has expanded significantly following the acquisition of three sites from BASF in 2015. As a result, Siegfried now offers more than 70 APIs and relies on world class distribution partners such as Univar to service our customers in over 80 countries."
Founded in 1924, Univar Inc. (NYSE: UNVR), is a global chemical and ingredients distributor and provider of value-added services, working with leading suppliers worldwide. Supported by a comprehensive team of sales and technical professionals with deep specialty and market expertise, Univar operates hundreds of distribution facilities throughout North America, Western Europe, Asia-Pacific and Latin America. Univar delivers tailored customer solutions through a broad product and services portfolio sustained by one of the most extensive industry distribution networks in the world. For more information, visit www.univar.com.
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, the USA, Malta, China, Germany and France. At the end of 2016, Siegfried reported annual sales of CHF 718 million and employs approximately 2300 employees at nine locations on three continents. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN). Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediates and controlled substances, and provides development and production services for finished dosage forms including sterile filling.
Cautionary Statements Regarding Forward-Looking Statements
This press release may contain forward-looking statements based on current assumptions and forecasts made by Siegfried Group management and other information currently available to the Siegfried Group. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Siegfried Holding AG does not intend, and does not assume any liability whatsoever, to update these forward-looking statements or to conform them to future events or developments.
SOURCE Univar Canada Ltd.
For further information: Univar Media Relations, +1 331-777-6176, firstname.lastname@example.org or Siegfried Holding AG Media Relations: Peter Gehler, Chief Communications Officer, email@example.com, Tel. +41 62 746 11 48, Mobile +41 79 416 41 16, http://www.univar.com